Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma

Conclusion: N  + GC displayed good efficacy in the second line or later treatment among patients with LSCC. This study suggested that N + GC is a useful option even after second-line treatment of advanced-stage or recurrent LSCC, although the management of adverse events is essential.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research